Détail du document
Identifiant
oai:HAL:hal-04054117v1
Sujet
Parkinson's disease Genetics Molecular Pathogenesis [SCCO]Cognitive scienceAuteur
Lesage, Suzanne Trinh, JoanneLangue
enEditeur
HAL CCSD
Catégorie
CNRS - Centre national de la recherche scientifique
Année
2023
Date de référencement
15/12/2023
Mots clés
including parkinsonism special issue genetics disease parkinsonRésumé
Parkinson's disease (PD) is a common and incurable neurodegenerative disease, affecting 1% of the population over the age of 65.
Although the disease remains defined clinically by its cardinal motor manifestations and pathologically by substantia nigra neuronal loss in association with intraneuronal Lewy bodies, the molecular mechanisms that lead to neurodegeneration remains elusive.
It is becoming increasingly clear that genetic factors contribute to its complex pathogenesis.
More than 23 loci and 13 genes, including LRRK2, SNCA, GBA1, PRKN, PINK1, and PARK7/DJ-1 clearly linked to inherited forms of Parkinsonism have been identified to date.
The knowledge acquired from their protein products has revealed pathways of neurodegeneration that can be shared by Mendelian and sporadic Parkinsonism, including synaptic, lysosomal, mitochondrial and immune-mediated mechanisms of pathogenesis.
This special issue "Parkinson's Disease: Genetics and Pathogenesis" collects 12 high-quality papers, including seven original research articles, and five reviews, that seeks to deepen the knowledge of multiple aspects related to Parkinsonism.
Lesage, Suzanne,Trinh, Joanne, 2023, Special Issue "Parkinson's Disease: Genetics and Pathogenesis";Numéro spécial: maladie de Parkinson et sa pathogénicité;Special Issue "Parkinson's Disease: Genetics and Pathogenesis": Editorial Letter, HAL CCSD
Real-world efficacy, roll-out and uptake of intramuscular tixagevimab/cilgavimab as COVID-19 pre-exposure prophylaxis in people with multiple sclerosis and neuroimmunological conditions during the COVID-19 pandemic
pwnic eligible pwms assess received covid-19 tixagevimab/cilgavimab uptake
